- AstraZeneca, Ionis drug fails big heart disease study in major setbackEplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.BioPharma Dive · 19d ago↗ source
- Who’s going to run the FDA?RFK Jr.'s list of Covid vaccine injuries, a father's quest to cure his daughter, and more health news from Morning RoundsSTAT · 19d ago↗ source
- GSK walks away from Alector pact as immuno-neurology bet fizzlesAfter two high-profile trial failures over the past year, GSK is breaking off a deal that features $700 million upfront that it signed with Alector for neurodegenerative disease treatments. GSK’s e…Endpoints · 19d ago